linjc16/ctgov huggingface dataset:
Properties and Clinical Performance of Zirconia-based Dental Ceramics

Study Overview
=================
Brief Summary
-----------------
The objectives of this study are to determine the clinical performance of zirconia-based dental prostheses and their related properties.

Detailed Description
-----------------
Zirconia has been used in dentistry since 2000 for constructing fixed partial denture. Its advantages are high fracture resistance, excellent biocompatibility, moderate opacity, etc. Because the increase in demand for more esthetic restoration, zirconia becomes more popular for use as a core material for all-ceramic systems. Its properties have been investigated extensively in many in vitro studies. However, clinical performance of zirconia-based restorations would require a period of time before the results can be assessed. Currently, there are not much results regarding clinical performance of zirconia-based prosthesis and more information are required for future research.

Official Title
-----------------
Properties and Clinical Performance of Zirconia-based Dental Ceramics

Conditions
-----------------
Dental Restoration Wear

Intervention / Treatment
-----------------
* Other: ceramic crown


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Occlusion: At least 20 remaining teeth for each patient, and at least one posterior endodontically treated tooth with natural opposing teeth Bruxism: No evidence based on an intraoral exam Dental history: No evidence of either moderate or severe periodontal disease Medical history: Good to excellent general health Exclusion Criteria: Periodontal status: Pocket depth greater than 4 mm Occlusion: Evidence of bruxism or excessive clenching force, Abutment tooth that opposes a removable partial denture, Abutment teeth for fixed partial dentures, Gingival recession of an abutment tooth more than 1 mm from the cementoenamel junction, Tooth with first or second degree of tooth mobility, Tooth with extensive carious lesions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>crown for clasp | Other: ceramic crown<br>* Zirconia<br>* Other names: Zirconia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ceramic crown fracture |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| masticatory function |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
crowns, ceramics
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA

Study Overview
=================
Brief Summary
-----------------
A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast and lung cancers, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of lung cancer is urgently needed. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in lung cancer patients.

Official Title
-----------------
Clinical Trials on Detection of Lung Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells

Conditions
-----------------
Lung Cancer, Lung Cancer, Nonsmall Cell, Lung Cancer, Small Cell

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological confirmed lung cancer Exclusion Criteria: Pregnant women Minors (subjects less than 18 years of age) Prisoners Patients with known infectious disease, such as human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B, C Patients having other than one cancer Subjects unable to consent for themselves

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung Cancer<br>Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC) | |
| Control<br>Age and sex matched control individuals | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of lung cancer | The outcome is the methylation score, which combines the weighted methylation values of four CpGs. A threshold methylation score that differentiates between control and cancer individuals will be calculated from the training set of 100 patients. The model will be provided to the researchers: Methylation score=CG1*b1+CG2*b2+ CG3*b3+ CG4*b4 + e CG1 is the methylation value of the first CG b1 is the regression coefficient for the first CG and e equals the intercept. Investigators will develop the regression coefficient and intercept as well as the DNA methylation values for each patient for each CG. Investigators will first compute the polygenic methylation score for each patient. Then based on the computer threshold based on the training cohort will call the samples as lung cancer or not. | 6 months to 1 year |
HPV Vaccination in Women With Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France. Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population. The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.

Official Title
-----------------
HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region

Conditions
-----------------
Human Papillomavirus Infection

Intervention / Treatment
-----------------
* Other: Self-report Written Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: girls with Cystic Fibrosis followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA) aged 11 years or older Exclusion Criteria: - Refusal to respond to the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Cystic Fibrosis<br>Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older. | Other: Self-report Written Questionnaire<br>* Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Realization of human papillomavirus vaccination | The main outcome is the prevalence of human papillomavirus vaccination in young women with Cystic fibrosis. This data is collected using a questionnaire : HPV vaccination performed : yes/no | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of vaccine used | This data is collected using a questionnaire : bivalent (Cervarix®) or quadrivalent (Gardasil®) | 15 minutes | 
| Respect for the vaccinal plan | This data is collected using a questionnaire : number and dates of injections | 15 minutes | 
| Reasons for non-vaccination | In case of non-vaccination reasons are collected using a multiple choices questionnaire | 15 minutes |
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

Official Title
-----------------
A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Conditions
-----------------
Prostatic Neoplasms

Intervention / Treatment
-----------------
* Drug: Atrasentan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have been diagnosed with prostate cancer. Have a rising PSA while on hormone therapy or following surgical castration. Exclusion Criteria: Have evidence of distant metastatic disease on screening bone scan or CT scan. Have received cytotoxic chemotherapy. Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atrasentan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer. |  | Every 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hormone-Refractory Prostate Cancer
Effect of Magnesium Alginate in Infants With Gastroesophageal Reflux.

Study Overview
=================
Brief Summary
-----------------
Recurrent regurgitation stress the infants and their parents and often results in an inappropirate use of PPI prescription in infancy. The aim of this study is to evaluate the efficacy of Mg alginate in infants with symptoms of gastroesophageal reflux.

Official Title
-----------------
Effect of Magnesium Alginate in Infants With Gastroesophageal Reflux.

Conditions
-----------------
Gastro Esophageal Reflux

Intervention / Treatment
-----------------
* Dietary Supplement: Mg alginate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: symptoms suggestive of GER, evaluated through a validated questionnaire (Infant Gastroesophageal Reflux Questionnaire Revised: I-GERQ-R > 16) informed consent signed Exclusion Criteria: congenital or chronic diseases use of anti acid drugs

Ages Eligible for Study
-----------------
Minimum Age: 3 Weeks
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: Randomized controlled cross-over trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: thickened formula<br> | Dietary Supplement: Mg alginate<br>* Mg alginate after feedings<br>|
| Experimental: Mg alginate<br> | Dietary Supplement: Mg alginate<br>* Mg alginate after feedings<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infant Gastro-Esophageal Reflux Questionnaire Revised | 12-item validated questionnaire called Infant Gastro-Esophageal Reflux Questionnaire Revised (I-GERQ-R) which include different questions about regurgitation, crying, feeding and respiratory problems | through study completion, an average of 1 month |
7 Year Follow-up Study of the DanRisk Population

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: To investigate the incidence of cardiovascular events as well as progression of coronary artery calcium (CAC) in healthy middle-aged subjects over a period of 7 years, and the relation to traditional as well as new cardiovascular risk factors. METHODS: The Danrisk cohort was established in 2009-2010 based on random retrieval from the Danish national civil registry (N=1825). Initially, distribution of gender, area of residence and year of birth (1949 or 1959) were equal among the 4 involved centres (OUH, Svendborg, Vejle and Esbjerg). A total of 1257 subjects (69%) accepted the invitation to undergo cardiovascular risk evaluation including non-contrast enhanced cardiac CT-scan for CAC estimation, and a total of 1227 subjects were found free of cardiovascular disease (CVD) and diabetes (DM), and was included in the study back then. In 2014-2015 the DanRisk cohort was invited to a 5 year follow-up examination. The investigators examined a total of 1031 subjects (82%) in the investigators 4 regional centres. The follow-up examination included general health evaluation and estimation of CAC by non-contrast enhanced cardiac CT-scan. Information of death, cardiovascular events and medication usage was obtained from the Danish national patient register, the Danish register of causes of death and the Danish national database of reimbursed prescriptions in 2016.

Official Title
-----------------
Implication of a Coronary Calcium Screening Examination, Incidence of Cardiovascular Events and Progression of Coronary Artery Calcium Over up to 7 Year of Follow-up in a Danish Middle-aged General Population

Conditions
-----------------
Cardiovascular Disease, Coronary Artery Calcification, Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Born in either 1949 or 1959 Residence in/near one of the regional centres (Esbjerg, Svendborg, Vejle, Odense). Exclusion Criteria: Known cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incident CV event |  | 6.5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAC Progression |  | 5 years |
Antibacterial Effect of Chlorhexidine Added to the Preventive Protocol in Adolescent Special Needs

Study Overview
=================
Brief Summary
-----------------
This study ia conducted to know the antibacterial effect of chlorhexidine on the mouth flora speciallly in adolescent special needs who can't hold the tooth brush properly

Detailed Description
-----------------
This study ia conducted to know the antibacterial effect of chlorhexidine on the mouth flora speciallly in adolescent special needs who can't hold the tooth brush properly cause those have alot of problems concerning the accumulagio. Of plaque and so increased bacteria

Official Title
-----------------
Antibacterial Effect of Chlorhexidine Added to the Preventive Protocol in Adolescent Special Needs

Conditions
-----------------
Caries

Intervention / Treatment
-----------------
* Drug: Chlorhexidine varnish added to the preventive protocol
* Behavioral: Preventive protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of disability like special needs autism and down syndrome Exclusion Criteria: age below 13

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Comparator<br>Preventive protocol | Behavioral: Preventive protocol<br>* Preventive protocol<br>* Other names: Caries preventive protocol;|
| Experimental: Intervention<br>Adding chlorhexidine to the preventive protocol | Drug: Chlorhexidine varnish added to the preventive protocol<br>* Antibacterial agent varnish added to the preventive protocol<br>* Other names: Varnish;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Streptococcus mutans count | Antibacterial effect of chlorhexidine on streptococcus mutans count | 1 year |
HLA-DR Expression in Neonates After Cardiac Surgery Under Cardiopulmonary Bypass

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in neonates who underwent cardiac surgery with cardiopulmonary bypasss. We hypothesize that HLA-DR expression in neonates is predictive of septic complications after cardiopulmonary bypass

Official Title
-----------------
HLA-DR Expression in Neonates After Cardiac Surgery Under Cardiopulmonary Bypass

Conditions
-----------------
Cardiac Surgery

Intervention / Treatment
-----------------
* Other: Blood collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≤ 28 days Admission after cardiac surgery under cardiopulmonary bypass Exclusion Criteria: Lack of parental consent

Ages Eligible for Study
-----------------
Maximum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| neonates with cardiac surgery under cardiopulmonary bypass<br> | Other: Blood collection<br>* A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HLA-DR expression | Number of HLA-DR molecules per monocyte (AB/c) determined by flow cytometry on whole blood using a Quantibrite phycoerythrin fluorescence quantitation kit (BD Biosciences) Number of HLA-DR molecules per monocyte (AB/c) determined by flow cytometry on whole blood using a Quantibrite phycoerythrin fluorescence quantitation kit (BD Biosciences) | Preoperatively, and 1, 2, 3 and 4 days after the end of cardiopulmonary bypass | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokines measurements | Pro and anti-inflammatory cytokine concentrations in the plasma measured by multiplex immunoassay | Preoperatively, and 1, 2, 3 and 4 days after the end of cardiopulmonary bypass | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HLA-DR expression, cardiopulmonary bypass, neonate
Biomarkers in Obstructive Sleep Apnea Surgery

Study Overview
=================
Brief Summary
-----------------
Recent years have witnessed major advances in the understanding of the hormonal, metabolic, and biochemical changes that occur in obstructive sleep apnea (OSA). This project evaluates the biomarkers that measure the most significant health impacts of this disorder and creates a specimen bank that will facilitate evaluations of additional biomarkers in the future.

Detailed Description
-----------------
This is a case-control study to examine the relationship between obstructive sleep apnea (OSA) and elevated levels of leptin, homocysteine, and C-reactive protein (CRP) in moderate or severe OSA and control patients. This is followed by a prospective cohort study to examine the relationship between surgical treatment of moderate or severe OSA and serum levels of these biomarkers. The short-term goals of this study consider the abnormalities in biomarker levels associated with OSA and specific aspects of the disorder as well as whether the changes seen after surgical treatment of OSA mirror those demonstrated after efficacious non-surgical treatment. The long term goals are in two areas: 1) the development of measures to determine which patients require treatment for sleep-disordered breathing and to monitor the effectiveness of therapy, and 2) a deeper understanding of the connection between OSA and its adverse health consequences.

Official Title
-----------------
Biomarkers in Obstructive Sleep Apnea Surgery

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Procedure: Surgical treatment for OSA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OSA group is adults with moderate or severe OSA (apnea >= 15 based on preoperative sleep study) undergoing surgical treatment. Assessment is done prior to surgery. Control group is overweight (body mass >25) adults without OSA (apnea-hypopnea index <5 based on sleep study) or other sleep disorders. Assessment is prior to treatment.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Surgical treatment for OSA|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leptin, homocysteine, and C-reactive protein levels. |  | Before and after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive Sleep Apnea, Leptin, Homocysteine, C-reactive Protein